Literature DB >> 24481092

Evaluation of Tp-e interval and Tp-e/QT ratio in patients with rheumatoid arthritis.

Gu Rkan Acar1, Murat Akkoyun2, Alper Bugra Nacar2, Imran Dirnak2, Gözde Yıldırım Çetin3, Makbule Nur Yıldırım4, Cemil Zencir4, Kayıhan Karaman4, Mustafa Cetin4, Mehmet Sayarlıoğlu3.   

Abstract

OBJECTIVES: Several studies have suggested that the interval from the peak to the end of the electrocardiographic T wave (Tp-e) may correspond to the transmural dispersion of repolarization and that increased Tp-e interval and Tp-e/QT ratio are associated with malignant ventricular arrhythmias. The aim of this study was to evaluate ventricular repolarization by using the Tp-e interval and Tp-e/QT ratio in patients with rheumatoid arthritis (RA), and to assess the relation with inflammation. STUDY
DESIGN: Ninety-six patients (72 females, 24 males; mean age 43.8±11.8 years) with RA and 50 controls (35 females, 15 males; mean age 44.2±11.1 years) were included. From the 12-lead electrocardiogram, Tp-e interval and Tp-e/QT ratio were measured. Blood samples were taken for erythrocyte sedimentation rate (ESR) and plasma levels of C-reactive protein (CRP). These parameters were compared between groups. The relationship between ventricular repolarization and inflammation was assessed by Pearson correlation coefficients.
RESULTS: Tp-e interval and Tp-e/QT ratio were increased in RA patients compared to the controls (72.6±8.2 vs 66.4±8.5 ms, 0.20±0.02 vs 0.18±0.02; p<0.001 and p<0.001, respectively). The Tp-e interval was significantly correlated with CRP, ESR, and disease activity score (DAS-28) (r=0.56, p<0.001, r=0.57, p<0.001, and r=0.29, p=0.02, respectively). The Tp-e/QT ratio was also correlated with CRP, ESR, and DAS-28 score (r=0.43, p<0.001, r=0.53, p<0.001, and r=0.25, p=0.03, respectively).
CONCLUSION: In RA patients, the increased frequency of ventricular arrhythmias may be explained by increased indexes of ventricular repolarization and their relationship with inflammation.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24481092     DOI: 10.5543/tkda.2014.52959

Source DB:  PubMed          Journal:  Turk Kardiyol Dern Ars        ISSN: 1016-5169


  6 in total

1.  New markers for ventricular repolarization in coronary slow flow: Tp-e interval, Tp-e/QT ratio, and Tp-e/QTc ratio.

Authors:  Kayihan Karaman; Fatih Altunkaş; Mustafa Çetin; Metin Karayakali; Arif Arısoy; Ilker Akar; Cemil Zencir; Barış Aygüç; Ataç Çelik
Journal:  Ann Noninvasive Electrocardiol       Date:  2014-09-30       Impact factor: 1.468

Review 2.  Ventricular repolarization markers for predicting malignant arrhythmias in clinical practice.

Authors:  Yaniel Castro-Torres; Raimundo Carmona-Puerta; Richard E Katholi
Journal:  World J Clin Cases       Date:  2015-08-16       Impact factor: 1.337

3.  Evaluation of inhomogeneities of repolarization in patients with psoriasis vulgaris.

Authors:  Korhan Soylu; Sinan İnci; Gökhan Aksan; Gökay Nar; Esra Pancar Yüksel; Hande Serra Ocal; Mustafa Çapraz; Serkan Yüksel; Mahmut Şahin
Journal:  Arch Med Sci       Date:  2016-10-24       Impact factor: 3.318

4.  Assessment of myocardial repolarisation parameters in patients with familial Mediterranean fever.

Authors:  Kayihan Karaman; Metin Karayakali; Ertuğrul Erken; Ahmet Demirtaş; Mustafa Öztürk; Fatih Altunkaş; Arif Arisoy; Oğuzhan Ekrem Turan; Köksal Ceyhan; Ataç Çelik
Journal:  Cardiovasc J Afr       Date:  2017 May/Jun       Impact factor: 1.167

5.  Evaluation of ventricular repolarization features with novel electrocardiographic parameters (Tp-e, Tp-e/QT) in patients with psoriasis.

Authors:  Arif Arısoy; Kayıhan Karaman; Metin Karayakalı; Selami Demirelli; Havva Yıldız Seçkin; Ataç Çelik; Köksal Ceyhan
Journal:  Anatol J Cardiol       Date:  2017-12       Impact factor: 1.596

6.  The Assessment of Tp-e Interval and Tp-e/QT Ratio in Patients With Systemic Sclerosis.

Authors:  Çağrı Yayla; Müçteba Enes Yayla; Kadriye Gayretli Yayla; Ufuk Ilgen; Mehmet Kadri Akboğa; Nurşen Düzgün
Journal:  Arch Rheumatol       Date:  2016-01-28       Impact factor: 1.472

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.